Table 2.
Rheumatic disease characteristics of patients at the time of SARS-CoV-2 vaccination.*.
| Characteristic | All Rheumatic Disease Patients (N = 11,468) |
|---|---|
| Rheumatic disease diagnosis | |
| Rheumatoid arthritis | 6099 (53.2) |
| Other inflammatory arthritis† | 1959 (17.1) |
| Giant cell arteritis and/or polymyalgia rheumatica | 388 (3.4) |
| Systemic lupus erythematosus | 1479 (12.9) |
| AAV and other vasculitides † | 268 (2.3) |
| Other rheumatic disease‡ | 571 (5.0) |
| Multiple rheumatic diseases | 704 (6.1) |
| Immunomodulatory medications§ | |
| Hydroxychloroquine or chloroquine | 3751 (32.7) |
| Methotrexate | 4058 (35.4) |
| Mycophenolate mofetil or mycophenolic acid | 517 (4.5) |
| Other csDMARD¶ | 1829 (16.9) |
| tsDMARD/JAK inhibitor | 702 (6.1) |
| Anti-CD20 monoclonal antibody | 278 (2.4) |
| TNF inhibitor | 3142 (27.4) |
| IL-6 inhibitor | 458 (4.0) |
| CTLA-4 Ig | 370 (3.2) |
| IL-17, IL-12/23, or IL-23 inhibitor | 597 (5.2) |
| Other bDMARD# | 139 (1.2) |
| Cyclophosphamide | 69 (0.6) |
| Oral glucocorticoid | 1162 (10.1) |
AAV, anti-neutrophil cytoplasmic antibody-associated vasculitis; DMARD, disease-modifying antirheumatic drug; bDMARD, biologic DMARD; tsDMARD, targeted synthetic DMARD; JAK, Janus kinase; csDMARD, conventional synthetic DMARD; TNF, tumor necrosis factor; IL, interleukin; CTLA-4 Ig, cytotoxic T-lymphocyte associated protein 4 immunoglobulin.
Other inflammatory arthritis includes psoriatic arthritis, axial spondyloarthritis, and juvenile idiopathic arthritis.
Other vasculitis includes Takayasu arteritis, Behcet disease, and other miscellaneous vasculitis.
Other rheumatic disease includes Sjogren's syndrome, systemic sclerosis, mixed connective tissue disease, antiphospholipid antibody syndrome, and idiopathic inflammatory myositis).
All medications that a patient was receiving were included; thus, numbers do not add up to 100%. The most recent biologic DMARD prescribed prior to the index date was considered to be the active medication.
Other csDMARD includes leflunomide, azathioprine, sulfasalazine, apremilast, cyclosporine, and tacrolimus.
Other bDMARD includes B-cell activating factor inhibitor, IL-1 inhibitor, IL-5 inhibitor, and C5 inhibitor.